Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Patients receiving lumateperone 42 mg plus ADT had statistically significant and clinically meaningful improvement in depression symptoms and disease severity compared with those receiving placebo+ADT. Lumateperone+ADT was generally safe and well tolerated in patients with MDD with inadequate ADT response.
Authors
- Susan G. Kozauer
- Suresh Durgam (ORCID: https://orcid.org/0000-0001-6629-0619)
- Hassan Lakkis
- Susan G. Kornstein
- Willie Earley
- J.B. Edwards
- Yifan Mo
- Maurizio Fava
Institutions
- Johnson & Johnson (United States) (US)
- Harvard University (US)
- Virginia Commonwealth University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- American Journal of Psychiatry
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1176/appi.ajp.20250292
- Citations
- 3
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.73